<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 14:00-16:00 | **Pre-meeting Course: Clinical Topics** | Chairs: Guðrún Björk Reyndís dóttir and Sigríður Þ. Valtyßdóttir, Reykjavík, Iceland  
Venue: Fróði, deCODE auditorium, deCODE genetics, Sturlugata 8 |
| 14:00-14:30 | Seronegative polyarthritis – diagnosis and treatment | Katerina Chatzidionysiou, Stockholm, Sweden |
| 14:30-15:00 | Ultrasound – practical uses in rheumatology, with focus on giant cell arteritis and polymyalgia rheumatica | Marcin Milchert, Szczecin, Poland |
| 15:00-15:30 | CNS manifestations of autoimmune disease – diagnosis and management | Margreet Steup Beekman, Leiden, The Netherlands |
| 15:30-16:00 | Autoimmune disease and pregnancy – a practical approach | Karin Hellgren, Stockholm, Sweden |

**Wednesday August 31**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 09:00-11:45 | **Pre-meeting Course Research Topics** | Chairs: Gunnar Tómasson and Þorvarður Jón Löve, Reykjavík, Iceland  
Venue: Fróði, deCODE auditorium, deCODE genetics, Sturlugata 8 |
| 09:00-09:45 | Getting my paper published – what does an editor look for when making a decision? | Tore Kvien, Oslo, Norway  
Søren Jacobsen, Copenhagen, Denmark |
| 09:45-10:15 | Scientific data visualization: tables and graphs that get your message across | Maarten Boers, Amsterdam, The Netherlands |
| 10:15-11:00 | Using big data for health research: the era of digital epidemiology | Will Dixon, Manchester, UK |
| 11:00-11:45 | R is great. This is all you need to know to get started | Sigrún Helga Lund, Reykjavík, Iceland |

**Thursday September 1**
Thursday September 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45-13:55</td>
<td>Scandinavian Society of Rheumatology - General Assembly</td>
<td>Silfurberg B, Harpa</td>
</tr>
<tr>
<td>14:00</td>
<td>Exhibition opens</td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Keynote lectures</td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td><strong>Cardiovascular risk in rheumatoid arthritis</strong> – an overview</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Elisabet Svenungsson, Stockholm and Carl Turesson, Lund, Sweden</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venue: Silfurberg B, Harpa</td>
<td></td>
</tr>
<tr>
<td>14:30-14:55</td>
<td>NSAID, COX inhibitors and cardiovascular risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Þorvarður Jón Löve, Reykjavík, Iceland and Marcin Milchert, Szczecin, Poland</td>
<td></td>
</tr>
<tr>
<td>14:55-15:15</td>
<td>Oral presentation, abstract OP01: Has the improved management of newly diagnosed RA lowered the excess risk of acute coronary syndrome?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Þorvarður Jón Löve, Reykjavík, Iceland and Marcin Milchert, Szczecin, Poland</td>
<td></td>
</tr>
<tr>
<td>15:15-15:45</td>
<td>Coffee break and exhibition</td>
<td></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td>Keynote lectures</td>
<td></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>Polymyalgia rheumatica - A substantial knowledge gap</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Þorvarður Jón Löve, Reykjavík, Iceland and Marcin Milchert, Szczecin, Poland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venue: Silfurberg B, Harpa</td>
<td></td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Outcome measures for PMR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Þorvarður Jón Löve, Reykjavík, Iceland and Marcin Milchert, Szczecin, Poland</td>
<td></td>
</tr>
<tr>
<td>17:00-19:30</td>
<td>Opening lecture &amp; ceremony, welcome reception</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Optimal use of outcome measures in inflammatory arthritis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Þorvarður Jón Löve, Reykjavík, Iceland and Marcin Milchert, Szczecin, Poland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venue: Silfurberg B, Harpa</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tuulikki Sokka-Isler, Jyvaskyla, Finland</strong></td>
<td></td>
</tr>
</tbody>
</table>
Friday September 2

Industry-sponsored satellite symposium
Program I
Program II

Parallel scientific session (1)
**Rheumatoid arthritis - from basic mechanisms to the bedside**
Chairs: Guðrún Björk Reynisdóttir, Reykjavík, Iceland and Till Uhlig, Oslo, Norway
Venue: Silfurberg B, Harpa
09:10-09:40 From triggering to targeting in the molecular pathogenesis of RA
*Lars Klareskog, Stockholm, Sweden*
09:40-10:00 New insights into the early development of ACPA-positive RA
*Anca Catrina, Stockholm, Sweden*
10:00-10:20 The use of animal models for understanding the basic mechanism of RA
*Rikard Holmdahl, Stockholm, Sweden*
10:20-10:40 Oral presentation, abstract OP02: Toward next generation rheumatology: from clinical research to understanding and back
*Tom Huizinga, Leiden, The Netherlands*

Parallel scientific session (2)
**Clinical and mechanistic aspects of OA**
Chairs: Helgi Jónsson, Reykjavík, Iceland and Ida K. Haugen, Oslo, Norway
Venue: Ríma AB, Harpa
09:10-09:40 The pathophysiology of OA with a special focus on inflammation/metabolism
*Francis Berenbaum, Paris, France*
09:40-10:00 Underlying inflammatory mechanisms in hand OA and inflammation as target for treatment
*Margreet Kloppenburg, Leiden, The Netherlands*
10:00-10:20 Muscles, movement and knee pain
*Helgi Jónsson, Reykjavík, Iceland*
10:20-10:40 Oral presentation, abstract OP03: Metacarpal osteomyelitis is a rare differential diagnosis to common causes of hand pain, a case report
*Bill Aplin Frederiksen, Svendborg, Denmark*

Parallel scientific session (3)
**Debate: TNF alpha inhibitors and beyond in ankylosing spondylitis**
Chairs: Árni Jón Geirsson, Reykjavík, Iceland and Katerina Chatzidionysiou, Stockholm, Sweden
Venue: Kaldalón, Harpa
09:10-10:40 Do TNF alpha inhibitors affect structural changes?
09:10-09:40 *Filip van den Bosch, Ghent, Belgium (pro)*
09:40-10:10 *Walter Maksymowych, Alberta, Canada (con)*
10:10-10:25 Oral presentation, abstract OP04: HLA-B27 status is associated with TNF alpha inhibitor treatment outcomes in ankylosing spondylitis and non-radiographic axial spondyloarthritis. Observational cohort study from the nationwide DANBIO registry
*Bente Glinthøj, Gentofte, Denmark*
10:25-10:40 Oral presentation, abstract OP05: Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year results from a phase 3 trial (MEASURE 2)
*Tuulikki Sokka-Islser, Jyväskyla, Finland*
10:40-11:00 Poster session, coffee break and exhibition
**Guided poster tour (1)**, 3-4 oral poster presentations from posters 1-24, with Tue Wenzel Kragstrup, Aarhus, Denmark
Friday September 2, continued

**Parallel scientific session (1)**

**What is new in SLE and APS?**

- Chairs: Þórunn Jónsdóttir and Kristján Steinsson, Reykjavík, Iceland
- Venue: Kaldalón, Harpa
- 11:00-11:25 Re-defining lupus in molecular terms
  *Marta Alarcon, Granada, Spain*
- 11:25-11:50 Horizon scanning: new biological treatment for SLE
  *Iva Gunnarsdóttir, Stockholm, Swe*
- 11:50-12:15 The antiphospholipid syndrome (APS), in isolation or as a subset of SLE
  *Elisabet Svenungsson, Stockholm, Sweden*
- 11:15-12:30 Oral presentation, abstract OP06: Characterization of systemic lupus erythematosus subgroups with features of antiphospholipid or Sjögren's syndrome utilizing affinity proteomics
  *Helena Idborg, Stockholm, Sweden*

**Parallel scientific session (2)**

**First lessons from the introduction of biosimilars to rheumatology**

- Chairs: Björn Guðbjörnsson, Reykjavík, Iceland and Glenn Haugeberg, Bærum/Oslo, Norway
- Venue: Silfurberg B, Harpa
- 11:00-11:30 Biosimilars-international perspectives
  *Jonathan Kay, Boston, USA*
- 11:30-12:00 Insights from the SWITCH - study
  *Tore Kvien, Oslo, Norway*
- 12:00-12:20 Oral presentation, abstract OP07: Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry
  *Bente Glintborg, Gentofte, Denmark*

**Parallel scientific session (3)**

**Shaping of the immune repertoire by commensural microbiota**

- Chairs: Anca Catrina, Stockholm, Sweden and Filip van den Bosch, Ghent, Belgium
- Venue: Ríma AB, Harpa
- 11:00-11:35 The role of microbiome in immune homeostasis
  *Fina Kurreeman, Leiden, The Netherlands*
- 11:35-12:10 Microbiome links to arthritis - Where's the evidence?
  *Miika Arvonen, Kuopio, Finland*
- 12:10-12:30 Oral presentation, abstract OP08: The lung microbiome in rheumatoid arthritis and associated local/systemic autoimmunity
  *Vijay Joshua, Stockholm, Sweden*

**12:30-14:00 Poster session, lunch and exhibition**

**Industry-sponsored satellite symposium**

**Program III**
### Parallel scientific session (1)

**Central pain sensitization in rheumatologic diseases**  
Chairs: Arnór Víkingsson and Sigríður Zoega, Reykjavík, Iceland  
Venue: Ríma AB, Harpa  
14:00-14:25 Fibromyalgia – a real challenge  
*Arnór Víkingsson, Reykjavík, Iceland*  
14:25-14:50 Mechanisms of central sensitization in musculoskeletal pain  
*Lars Arendt-Nielsen, Aalborg, Denmark*  
14:50-15:15 Evaluation and treatment of central pain in sensitization in rheumatologic diseases  
*Yvonne C Lee, Boston, USA*

### Parallel scientific session (2)

**IgG4-related disease and other odd cases: Diagnostic and therapeutic challenges**  
Chairs: Sigríður Valtísdóttir, Reykjavík, Iceland and Tom Pettersson, Helsinki, Finland  
Venue: Kaldalón, Harpa  
14:00-14:15 Case presentation 1  
*Jón Atli Árnason, Wisconsin, USA*  
14:15-14:30 Case presentation 2  
*Árni Jón Geirsson, Reykjavík, Iceland*  
14:30-15:15 IgG4-related disease: How did we miss this for SO LONG  
*John Stone, Boston, USA*

### Parallel scientific session (3)

**Epidemiology to inform rheumatology**  
Chairs: Gunnar Tómasson, Reykjavík, Iceland and Johan Askling, Stockholm, Sweden  
Venue: Silfurberg B, Harpa  
14:00-14:35 What can we learn on the occurrence of systemic rheumatic diseases from environmental studies?  
*Alfred Mahr, Paris, France*  
14:35-15:00 Clinical epidemiology methods to identify best treatment options in rheumatology  
*Robin Christensen, Copenhagen, Denmark*  
15:00-15:15 Oral presentation, abstract OP09: Obesity is associated with worse clinical outcomes yet limited radiographic progression in early rheumatoid arthritis  
*Adrian Levitsky, Stockholm, Sweden*

15:15-15:35 **Poster session, coffee break and exhibition**  
**Guided poster tour (2),** 3-4 oral poster presentations from posters 25-49,  
with Katerina Chatzidonysioi, Stockholm, Sweden
### Parallel scientific session (1)

**Management of small vessel vasculitis: Current use of existing therapeutic agents and future treatments**

- **Chairs:** Birgir Már Guðbrandsson, Oslo, Norway and Sarah L. Mackie, Leeds, United Kingdom
- **Venue:** Ríma AB, Harpa
- **15:35-16:00** Overview of randomized controlled trials for ANCA-associated vasculitis  
  *Gunnar Tómasson, Reykjavík, Iceland*
- **16:00-16:25** Treatment of remission maintainance in ANCA-associated vasculitis  
  *Peter A. Merkel, Philadelphia, USA*
- **16:25-16:50** Management of EGPA: can data from AAV trials be extrapolated to EGPA (Churg-Strauss syndrome)?  
  *Alfred Mahr, Paris, France*

### Parallel scientific session (2)

**Pharmacoepidemiology in rheumatology**

- **Chairs:** Lene Dreyer, Gentofte, Denmark and Espen A. Haavardsholm, Oslo, Norway
- **Venue:** Silfurberg B, Harpa
- **15:35-16:05** Optimal use of low dose glucorticoids in inflammatory arthritis  
  *Maarten Boers, Amsterdam, The Netherlands*
- **16:05-16:30** Biologics and risk of malignancy - implications for regular screening?  
  *Johan Askling, Stockholm, Sweden*
- **16:30-16:50** Oral presentation, abstract OP10: Non-medical-switch from originator to biosimilar infliximab in patients with inflammatory arthritis - impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and DANBIO  
  *Bente Glintborg, Gentofte, Denmark*

### Parallel scientific session (3)

**Is the treat to target model applicable to crystal arthropathies?**

- **Chairs:** Jonathan Kay, Boston, USA and Valgerður Rós Sigurðardóttir, Falun, Sweden
- **Venue:** Kaldalón, Harpa
- **15:35-15:55** Pseudogout - what is new?  
  *Till Uhlig, Oslo, Norway*
- **15:55-16:20** Is it possible to treat to target in gout?  
  *Mats Dehlin, Gothenburg, Sweden*
- **16:20-16:40** Imaging of gout (dual energy CT)  
  *Martina Lohman, Helsinki, Finland*
- **16:40-16:50** Oral presentation, abstract OP11: Effect of bariatric surgery on the incidence of hyperuricemia and gout  
  *Cristina Maglio, Gothenburg, Sweden*

### Industry-sponsored satellite symposium

**Program IV**

- **17:40-18:00**
- **19:30-24:00** Congress dinner and party
### Saturday September 3

**Parallel scientific session (1)**

**Personalized medicine - how to treat the individual patient with RA**

- Chairs: Dan Nordström, Helsinki, Finland and Tom Huizinga, Leiden, The Netherlands
- Venue: Silfurberg B, Harpa
- 09:10-09:25 Treat to target: from evidence based knowledge to real-life care - still a gap?  
  *Sædís Sævarsdóttir, Stockholm, Sweden*
- 09:25-09:50 Can nonbiologic DMARD be as effective as biologic DMARDs if used the right way?  
  *Toulikki Sokka-Islor, Jyväskyla, Finland*
- 09:50-10:20 First lessons learned in the NORDSTAR study, a Nordic study on treatment of RA  
  *Anna Rudin, Gothenburg, Sweden*
- 10:20-10:40 Oral presentation, abstract OP12: Baricitinib versus placebo or adalimumab in patients with active RA an inadequate response to background methotrexate therapy: Results of a phase 3 study  
  *Esbjörn Larsson, Stockholm, Sweden*

**Parallel scientific session (2)**

**What is new in connective tissue diseases**

- Chairs: Ingrid Lundberg and Iva Gunnarsson, Stockholm, Sweden
- Venue: Kaldalón, Harpa
- 09:10-09:35 New autoantibodies to help diagnosis and understanding pathogenesis  
  *Ingrid Lundberg*
- 09:35-10:05 Searching for common rare genetic variants in SLE, Sjögren’s syndrome and myositis (DISSECT project)  
  *Lars Rönnblom, Uppsala, Sweden*
- 10:05-10:25 Anti-synthetase syndrome - treatment and outcome  
  *Öyvind Molberg, Oslo, Norway*
- 10:25-10:40 Oral presentation, abstract OP13: Characterization of extracellular histidyl-tRNA synthetase in myositis  
  *Per-Johan Jakobsson, Stockholm, Sweden*

**Health professionals session**

**Life-style factors in rheumatic diseases**

- Chairs: Elínborg Stefánsdóttir, Reykjavik, Iceland and Per Johansen, Holbæk, Denmark
- Venue: Ríma AB, Harpa
- 09:10-09:35 Lifestyle factors influencing the risk of osteoporosis  
  *Karen Hansen, Wisconsin, USA*
- 09:35-10:05 Exercise as treatment for myositis  
  *Li Alemo Munters, Stockholm, Sweden*
- 10:05-10:25 Life-style factors in rheumatic diseases  
  *Sædís Sævarsdóttir, Stockholm, Sweden*
- 10:25-10:40 Oral presentation, abstract OP14: How do women with lupus manage fatigue? A focus group study  
  *Anne Örnholt Kier, Region Midtjylland, Denmark*

**10:40-11:00 Poster session, coffee break and exhibition**

**Guided poster tour (3)**, 3-4 oral poster presentations from posters 50-72, with Ida K. Haugen, Oslo, Norway
### Historic session - Narrative medicine in rheumatology

**Chairs:** Gerður Gröndal, Reykjavík, Iceland and Lars Klareskog, Stockholm, Sweden  
**Venue:** Kaldalón, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>Jan Waldenström, a Linnéan at the bedside</td>
<td><strong>Frank Wollheim, Lund, Sweden</strong></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>History of rheumatology in the Nordic countries</td>
<td><strong>Ido Leden, Kristianstad, Sweden</strong></td>
</tr>
<tr>
<td>12:00-12:25</td>
<td>Did the heros of the sagas suffer from psychiatric diseases?</td>
<td><strong>Óttar Guðmundsson, Reykjavík, Iceland</strong></td>
</tr>
<tr>
<td>12:25-12:40</td>
<td>Oral presentation, abstract OP15: Egill Skallagrímsson: How a Viking's bone disease led to the cure of osteoporosis</td>
<td><strong>Peter John Ornsby Stride, Queensland, Australia</strong></td>
</tr>
</tbody>
</table>

### Scientific session

**Use of imaging for disease activity assessment in rheumatic diseases**  
**Chairs:** Mikkel Östergard, Copenhagen, Denmark and Laura Pirilä, Turku, Finland  
**Venue:** Silfurberg B, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>Is ultrasound useful for guiding treatment of RA?</td>
<td><strong>Espen A. Haavardsholm, Oslo, Norway</strong></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>The use of PET-CT in large vessel vasculitides</td>
<td><strong>Birgir Már Guðbrandsson, Oslo, Norway</strong></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Imaging as diagnostic tool in OA</td>
<td><strong>Ida K. Haugen, Oslo, Norway</strong></td>
</tr>
</tbody>
</table>

### Health professionals session

**Patient empowerment - patient self monitoring**  
**Chairs:** Susanne Pettersson, Stockholm, Sweden and Halldóra Ingvadóttir, Reykjavík, Iceland  
**Venue:** Ríma AB, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>Nurse’s role in unmet management and treatment needs of rheumatic patients</td>
<td><strong>Yvonne van Eijk, Maastricht, The Netherlands</strong></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Patient involvement from the patient perspective</td>
<td><strong>Connie Ziegler, Copenhagen, Denmark</strong></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Exercise as treatment in rheumatic and musculoskeletal diseases</td>
<td><strong>Rikke Moe, Oslo, Norway</strong></td>
</tr>
</tbody>
</table>

**12:30-14:00** Poster session, lunch and exhibition

### Industry-sponsored satellite symposium

**Program V**
### Parallel scientific session (1)

**The psoriatic disease concept - From skin, to joints and beyond**

- Chairs: Þorvarður Jón Löve, Reykjavík Iceland and Marrku Kauppi, Tampere, Finland
- Venue: Silfurberg B, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:20</td>
<td>Psoriatic arthritis, an update</td>
</tr>
<tr>
<td></td>
<td><em>Arthur Kavanaugh, San Diego, USA</em></td>
</tr>
<tr>
<td>14:20-14:35</td>
<td>Risk factors for psoriatic arthritis - why does psoriasis spill over into joints?</td>
</tr>
<tr>
<td></td>
<td><em>Þorvarður Jón Löve, Reykjavík, Iceland</em></td>
</tr>
<tr>
<td>14:35-14:55</td>
<td>Psoriatic arthritis treatment - predictors of treatment response in routine care</td>
</tr>
<tr>
<td></td>
<td><em>Bente Glintborg, Gentofte, Denmark</em></td>
</tr>
<tr>
<td>14:55-15:15</td>
<td>Living and dying with psoriatic arthritis - comorbidities</td>
</tr>
<tr>
<td></td>
<td><em>Glenn Haugeberg, Bærum/Oslo, Norway</em></td>
</tr>
</tbody>
</table>

### Parallel scientific session (2)

**Systemic sclerosis, a challenge to diagnose and treat**

- Chairs: Ragnar Gunnarsson, Oslo, Norway and Annica Nordin, Stockholm, Sweden
- Venue: Kaldalón, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:25</td>
<td>Autologous hematopoietic stem cell transplantation in diffuse cutaneous systemic sclerosis</td>
</tr>
<tr>
<td></td>
<td><em>Jaap M van Laar, Utrecht, The Netherlands</em></td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>Novel molecular and epidemiological features of systemic sclerosis</td>
</tr>
<tr>
<td></td>
<td><em>Kristofer Andréasson, Lund, Sweden</em></td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>Cardiopulmonary risk assessment in systemic sclerosis</td>
</tr>
<tr>
<td></td>
<td><em>Anna-Maria Hoffmann-Vold, Oslo, Norway</em></td>
</tr>
</tbody>
</table>

### Health professionals session

**Access to professional care in the Nordic countries**

- Chairs: Ragnar Freyr Ingvarsson, Reykjavík, Iceland and Cecilia Carlens, Stockholm, Sweden
- Venue: Ríma AB, Harpa

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:25</td>
<td>Person-centred care in rheumatology nursing</td>
</tr>
<tr>
<td></td>
<td><em>Ingrid Larsson, Halmstad, Sweden</em></td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>How do we make rheumatology an even more attractive speciality?</td>
</tr>
<tr>
<td></td>
<td><em>Anders Bengtsson, Lund, Sweden</em></td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>Oral presentation, abstract OP16: The rate of nurse consultation is higher with senior physicians compared to junior physicians: impact on economy</td>
</tr>
<tr>
<td></td>
<td><em>Merete Birkholm Hansen, Svendborg, Denmark</em></td>
</tr>
<tr>
<td>15:15-15:35</td>
<td>Poster session, coffee break and exhibition</td>
</tr>
</tbody>
</table>
### Discussion

**The future of Rheumatology**

Chairs: Sædis Sævarsdóttir, Stockholm, Sweden and Øyvind Molberg, Oslo, Norway  
Venue: Kaldalón, Harpa

15:35-16:05 Scandinavian Congress of Rheumatology award recipients  
*Katerina Chatzidionysiou, Stockholm, Sweden*  
*Ida K. Haugen, Oslo, Norway*  
*Tue Wenzel Kragstrup, Aarhus, Denmark*

16:05-16:25 Future of SJR  
*Søren Jacobsen, Copenhagen, Denmark*

16:25-16:50 How to make the most out of our Scandinavian registries  
*Johan Askling, Stockholm, Sweden*

---

### Health professionals session

**E-health and new tools to improve health for patients**

Chairs: Gunnar Tómasson, Reykjavík, Iceland and Ragnar Gunnarsson, Oslo, Norway  
Venue: Ríma AB, Harpa

15:35-16:00 Patients own management of blood tests  
*Susanne Pettersson, Stockholm, Sweden*

16:00-16:30 Benefits and challenges associated with involvement of patients in the development of evidence-based eHealth services  
*Pernilla Åsenlöf, Uppsala, Sweden*

16:30-16:50 Oral presentation, abstract OP17: Clinical decision support system in osteoporosis in comparison to NOGG guidelines and an osteology specialist  
*Haukur Týr Guðmundsson, Reykjavík, Iceland*